Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Mallinckrodt
US Army
Cipla
Deloitte
Julphar
Express Scripts
Federal Trade Commission
Teva

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,695,578

« Back to Dashboard

Summary for Patent: 4,695,578
Title: 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
Abstract:The invention relates to compounds of formula (I). ##STR1## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group, and one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-(C.sub.1-3) alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates, e.g. hydrates thereof. The compounds are potent selective antagonists at "neuronal" 5-hydroxytryptamine receptors and are useful in the treatment of migraine and psychotic disorders such as schizophrenia.
Inventor(s): Coates; Ian H. (Hertfordshire, GB2), Bell; James A. (Royston, GB2), Humber; David C. (Ealing, GB2), Ewan; George B. (Gerrard's Cross, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:06/931,032
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 4,695,578

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,695,578

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8401888Jan 25, 1984
United Kingdom8425959Oct 15, 1984
United Kingdom8501727Jan 23, 1985
United Kingdom8501728Jan 23, 1985

International Patents Family Members for US Patent 4,695,578

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 392276 ➤ Subscribe
Austria A20485 ➤ Subscribe
Australia 3809785 ➤ Subscribe
Australia 5261486 ➤ Subscribe
Australia 579132 ➤ Subscribe
Australia 583343 ➤ Subscribe
Belgium 901576 ➤ Subscribe
Canada 1252793 ➤ Subscribe
Switzerland 664152 ➤ Subscribe
China 1011237 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Citi
Chubb
Queensland Health
Cerilliant
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot